BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

Stock Information for Duos Technologies Group Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Duos Technologies Group Inc - Ordinary Shares

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
BrainStorm Issues 2024 Letter to Shareholders
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.